Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 15;11(1):62-67.
doi: 10.1055/s-0041-1731599. eCollection 2022 Jan.

Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data

Sanjeev Kumar Sharma  1 , Dharma Choudhary  1 , Divya Doval  1 , Vipin Khandelwal  1 , Rasika Setia  1 , Tina Dadu  1 , Anil Handoo  1
Affiliations

Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data

Sanjeev Kumar Sharma et al. South Asian J Cancer. .

Abstract

Sanjeev Kumar SharmaHematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haploidentical transplantations as an alternative treatment modality, more patients are opting for HSCT as a definite treatment for hematological malignancies. We report here the real-world data and outcome of HSCT done for hematological malignancies at our transplant center. Five hundred and sixteen patients underwent HSCT from August 2010 to November 2019. The most common indications for allogeneic and autologous HSCT were acute myeloid leukemia and multiple myeloma, respectively. The 5-year overall survival and disease-free survival for all transplants were 65% and 33%, respectively. Though outcome of matched sibling donor allogeneic transplant is better than haploidentical donor (HID) transplant, patients having only HID can still be considered for allogeneic HSCT for high-risk diseases. The most common cause of death was infections followed by relapse of the disease.

Keywords: GVHD; allogeneic; haploidentical; infections; leukemia; lymphoma; matched sibling donor; myeloma; overall survival; stem cell transplant.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

None
Sanjeev Kumar Sharma
Fig. 1
Fig. 1
The overall survival of all hematological malignancies.
Fig. 2
Fig. 2
The disease-free survival of hematological malignancies.
See this image and copyright information in PMC

References

    1. Bacigalupo A, Ballen K, Rizzo D. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633. - PMC - PubMed
    1. Sharma S K, Choudhary D, Gupta N. Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis. 2014;6(01):e2014046. - PMC - PubMed
    1. Malhotra P, Yanamandra U, Khadwal A. Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. Indian J Hematol Blood Transfus. 2018;34(02):261–267. - PMC - PubMed
    1. Kumar L, Ramavath D, Kataria B. for AIIMS Myeloma Group. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome. Indian J Med Res. 2019;149(06):730–739. - PMC - PubMed
    1. Kulkarni U, Devasia A J, Korula A. Clinical outcomes in multiple myeloma post-autologous transplantation-a single centre experience. Indian J Hematol Blood Transfus. 2019;35(02):215–222. - PMC - PubMed